ESC2016:血脂异常管理 哪些才是目标?

2016-08-27 麦憬霆 心血管时间

血脂管理是心血管疾病治疗的重要手段之一。总胆固醇(TC)、高密度脂蛋白(HDL-c)、低密度脂蛋白(LDL-c)和甘油三酯(TG)是临床上常用的血脂检查指标。那么,当患者发生血脂异常时,这些指标的管理目标是什么

血脂管理是心血管疾病治疗的重要手段之一。总胆固醇(TC)、高密度脂蛋白(HDL-c)、低密度脂蛋白(LDL-c)和甘油三酯(TG)是临床上常用的血脂检查指标。那么,当患者发生血脂异常时,这些指标的管理目标是什么?


2016 年 8 月 27 日~31 日,欧洲心脏病学会年会(ESC2016)在意大利罗马盛大召开。来自意大利的 Luigina GUASTI 教授在 ESC 2016 上带来她的建议。


LDL-c :不同风险级别患者有不同目标水平



图 1 大会现场图片


血脂管理的首要目标显而易见:LDL-c。


为了使患者达到正常的 LDL-c 水平,临床医生应对每个患者进行个体化的风险评估。ESC/EAS 指南建议 40 岁到 65 岁成人结合 LDL-c 指标水平,以估算 10 年心血管疾病死亡风险,并筛选出不同风险级别的患者,进行个体化治疗。


图 2 高风险国家 10 年心血管疾病死亡风险评分表


图 3 低风险国家 10 年心血管疾病死亡风险评分表


GUASTI 教授介绍,根据最新发布的 2016 ESC 心血管疾病防治指南,以上评分能够帮助临床医生识别不同风险级别的患者,而不同风险级别的患者有不同的 LDL-c 目标水平:


低到中度风险患者(评分<5%),LDL-c 目标水平<70 mg/dL;


高风险患者(评分 ≥ 5% 并 <10%),LDL-c 目标水平<100 mg/dL;


极高风险患者(评分 ≥ 10%),LDL-c 目标水平<115 mg/dL。



图 4 血脂指标水平控制的建议


那么,问题来了:如何通过治疗达到不同的 LDL-c 目标水平? 研究结果显示,中效他汀类药物能使 LDL-c 下降 30%~50%,而强效他汀类药物能有效降低 LDL-c  50% 以上。与此同时,PCSK9 抑制剂也能有效降低 LDL-c 达 48.86%。


此外,临床上不乏家族性高胆固醇症(FH)患者,对此 GUASTI 教授也给出了诊断建议:


>8 分,可诊断为 FH;


6~8 分,很可能是 FH;


3~5 分,可能是 FH。


对于 FH 患者,LDL-c 的管理目标水平应以年龄区分:


儿童<135 mg/dL;


成人<100 mg/dL;


CHD 或糖尿病患者<70 mg/dL。


TG、HDL-c :暂无明确目标水平


对于 TG 和 HDL-c ,指南暂无明确的目标水平推荐。但建议男性 HDL-c > 40 mg/dL 、女性 HDL-c > 45 mg/dL ,TG <150 mg/dL,这样患者风险较低。


GUASTI 教授建议,患者可通过戒烟、运动和饮食改善使 HDL-c 和 TG 达到正常水平。



图 5 血脂异常目标水平管理

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=134822, encodeId=285413482217, content=文章很好值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 25 08:56:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774540, encodeId=a5a11e74540ab, content=<a href='/topic/show?id=daa989924da' target=_blank style='color:#2F92EE;'>#血脂异常管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89924, encryptionId=daa989924da, topicName=血脂异常管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Sep 01 00:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107669, encodeId=db8310e669a7, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Tue Aug 30 19:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253720, encodeId=a5831253e20c6, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Aug 29 14:29:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106732, encodeId=eb1b106e32ff, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:05:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106573, encodeId=2b981065e374, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106574, encodeId=2c171065e42c, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=)]
    2016-09-25 1e10c84am36(暂无匿称)

    文章很好值得关注

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=134822, encodeId=285413482217, content=文章很好值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 25 08:56:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774540, encodeId=a5a11e74540ab, content=<a href='/topic/show?id=daa989924da' target=_blank style='color:#2F92EE;'>#血脂异常管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89924, encryptionId=daa989924da, topicName=血脂异常管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Sep 01 00:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107669, encodeId=db8310e669a7, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Tue Aug 30 19:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253720, encodeId=a5831253e20c6, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Aug 29 14:29:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106732, encodeId=eb1b106e32ff, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:05:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106573, encodeId=2b981065e374, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106574, encodeId=2c171065e42c, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=134822, encodeId=285413482217, content=文章很好值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 25 08:56:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774540, encodeId=a5a11e74540ab, content=<a href='/topic/show?id=daa989924da' target=_blank style='color:#2F92EE;'>#血脂异常管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89924, encryptionId=daa989924da, topicName=血脂异常管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Sep 01 00:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107669, encodeId=db8310e669a7, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Tue Aug 30 19:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253720, encodeId=a5831253e20c6, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Aug 29 14:29:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106732, encodeId=eb1b106e32ff, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:05:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106573, encodeId=2b981065e374, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106574, encodeId=2c171065e42c, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=)]
    2016-08-30 大旺旺

    值得学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=134822, encodeId=285413482217, content=文章很好值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 25 08:56:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774540, encodeId=a5a11e74540ab, content=<a href='/topic/show?id=daa989924da' target=_blank style='color:#2F92EE;'>#血脂异常管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89924, encryptionId=daa989924da, topicName=血脂异常管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Sep 01 00:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107669, encodeId=db8310e669a7, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Tue Aug 30 19:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253720, encodeId=a5831253e20c6, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Aug 29 14:29:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106732, encodeId=eb1b106e32ff, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:05:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106573, encodeId=2b981065e374, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106574, encodeId=2c171065e42c, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=134822, encodeId=285413482217, content=文章很好值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 25 08:56:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774540, encodeId=a5a11e74540ab, content=<a href='/topic/show?id=daa989924da' target=_blank style='color:#2F92EE;'>#血脂异常管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89924, encryptionId=daa989924da, topicName=血脂异常管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Sep 01 00:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107669, encodeId=db8310e669a7, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Tue Aug 30 19:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253720, encodeId=a5831253e20c6, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Aug 29 14:29:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106732, encodeId=eb1b106e32ff, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:05:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106573, encodeId=2b981065e374, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106574, encodeId=2c171065e42c, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=)]
    2016-08-29 医路开来

    学习啦,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=134822, encodeId=285413482217, content=文章很好值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 25 08:56:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774540, encodeId=a5a11e74540ab, content=<a href='/topic/show?id=daa989924da' target=_blank style='color:#2F92EE;'>#血脂异常管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89924, encryptionId=daa989924da, topicName=血脂异常管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Sep 01 00:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107669, encodeId=db8310e669a7, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Tue Aug 30 19:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253720, encodeId=a5831253e20c6, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Aug 29 14:29:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106732, encodeId=eb1b106e32ff, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:05:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106573, encodeId=2b981065e374, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106574, encodeId=2c171065e42c, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=)]
    2016-08-29 doctorJiangchao

    继续学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=134822, encodeId=285413482217, content=文章很好值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 25 08:56:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774540, encodeId=a5a11e74540ab, content=<a href='/topic/show?id=daa989924da' target=_blank style='color:#2F92EE;'>#血脂异常管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89924, encryptionId=daa989924da, topicName=血脂异常管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu Sep 01 00:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107669, encodeId=db8310e669a7, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Tue Aug 30 19:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253720, encodeId=a5831253e20c6, content=<a href='/topic/show?id=cbd48992056' target=_blank style='color:#2F92EE;'>#血脂异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89920, encryptionId=cbd48992056, topicName=血脂异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Aug 29 14:29:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106732, encodeId=eb1b106e32ff, content=学习啦,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Mon Aug 29 10:05:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106573, encodeId=2b981065e374, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106574, encodeId=2c171065e42c, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 29 07:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=)]
    2016-08-29 doctorJiangchao

    继续关注

    0

相关资讯

中国成人血脂异常防治指南(修订版)正式定稿

2016年1月31日,《中国成人血脂异常防治指南(2016年修订版)》定稿会在京召开。会议由诸骏仁教授和高润霖院士主持,张运、葛均波、霍勇、陆国平、赵冬、赵水平、李建军等共45位血脂异常防治专家出席了会议。《中国成人血脂异常防治指南》修订工作于2013年11月27日正式启动,经过文献检索评估、专题研讨、分专题组起草等程序,历时两年最终完成修订工作。本次修订工作主要依据中国人群的循证证据和中国人群特

BMJ Open:他汀对血脂异常发生率似乎没什么卵用

血脂异常是心血管疾病主要危险因素,而心血管疾病又是全球范围内主要死亡原因。研究者进行了一项横断面研究,探究初级医疗保健机构加拿大人群中血脂异常发生情况。该研究共纳入了134074名>20岁非妊娠成年人,通过加拿大指南识别血脂异常,使用多因素回顾分析比较血脂异常情况。研究数据显示,纳入人群平均年龄59.2岁,其中55.8%是女性。34.8%的参与者没有血脂异常,有1种、2种、3种血脂异常的参与者分别

2016USPSTF建议声明——儿童和青少年血脂异常的筛查发布

2016年8月,美国预防医学工作组(USPSTF)发布了儿童和青少年血脂异常的筛查建议,该建议是对2007年儿童,青少年和年轻成人血脂议程筛查建议的更新,建议指出当前证据不足以评估儿童,青少年血脂异常筛查获益和危害的平衡。全文获取:下载地址:指南下载  (需要扣积分2分, 梅斯医学APP免积分下载)

2015年《血脂异常老年人使用他汀类药物中国专家共识》解读

老年人是动脉粥样硬化性心血管疾病(ASCVD)的高危人群,是他汀类药物治疗的适宜人群。而出于对老年人应用他汀类药物是否获益及安全性的担忧,老年人他汀类药物的应用严重不足。2015年第5期《中华内科杂志》发表了《血脂异常老年人使用他汀类药物中国专家共识)》(以下简称“共识”)。本版共识是在2010年发表的《血脂异常老年人使用他汀类药物中国专家共识》的基础上,结合近年血脂异常治疗的进展,综合众多老

郭艺芳:降胆固醇治疗策略的新趋势

河北省人民医院 郭艺芳近日,有三则关于降胆固醇治疗的消息在各类媒体广泛传播:其一,IMPROVE-IT研究结果在新英格兰医学杂志正式发表;其二,选择性胆固醇吸收抑制剂临床应用中国专家共识正式发表;其三,FDA将就两种降胆固醇新药PCSK9抑制剂Alirocumab与Evolocumab举行专家听证会。综合分析这三则消息,可以看出降胆固醇的药物治疗策略正从他汀类药物一枝独秀的局面转变为以他汀为主、胆

孙艺红/胡大一:降低LDL-C是硬道理

一、国际指南的变化与异同过去一年中,国际多个学术组织陆续更新了血脂异常临床治疗指南。这些指南因制定策略和方法不同,临床管理策略建议也各有特色。其共同之处包括:(1)调脂治疗主要目的是降低ASCVD风险。ASCVD不仅包括冠心病,也包括动脉粥样硬化所致缺血性卒中和外周动脉粥样硬化性疾病。且糖尿病和慢性肾病患者也被列为与ASCVD危险等同的极高危人群。(2)推荐他汀类药物作为降低ASCVD风险的主